Purpose To determine if the timing of whole brain radiotherapy (WBRT) with respect to chemotherapy with cisplatin and vinorelbine would influence survival in patients with nonsmall-cell lung cancer (NSCLC) and concurrent brain metastasis.
Summary
Purpose To determine if the timing of whole brain radiotherapy (WBRT) with respect to chemotherapy with cisplatin and vinorelbine would influence survival in patients with nonsmall-cell lung cancer (NSCLC) and concurrent brain metastasis.
Patients and methods One hundred seventy-six patients with brain metastasis from NSCLC were included in the study between July 1995 and October 1997 All patients received chemotherapy with cisplatin 100 mg/m 2 on day 1 and vinorelbine 30 mg/m 2 on days 1, 8, 15, 22 Cycles were repeated every four weeks. Evaluation of response was performed after two, four or six cycles After two cycles, chemotherapy was administered to the responders to a maximum of six cycles. Patients were randomised to receive WBRT 30 Gy/10 fx/12 days and delayed corticosteroids, (arm A) for the intracranial nonresponders, or early on day 1 to 12 during the first cycle of chemotherapy (arm B) Results One hundred seventy-one patients were eligible, eighty-six in arm A and eighty-five in arm B, none had received prior chemotherapy; seventy-six and seventy-three, respectively, were assessable for response There was a 21% overall objective response rate (OR) (with 1 complete response and 17 partial responses) after two cycles of chemotherapy alone (arm A) and a 20% OR (with 17 partial responses) to chemotherapy and early WBRT (arm B). The intracranial OR was 27% and 33%, respectively (P -0 12) The six months survival rate (46% and 40%) and the median survival duration (24 and 21 weeks, respectively) were not significantly different between the two arms (P = 0 83, log-rank test) The major toxicity was severe or life-threatening neutropenia (grade 4), which occurred in 35% of arm A patients and 36% of arm B patients. There were thirteen treatment-related deaths (six in arm A and seven in arm B). There was no difference between the arms for haematological and neuro-toxicities.
Introduction
The development of brain metastases is a frequent occurrence in the clinical evolution of non-small-cell lung cancer (NSCLC), and their presence considerably worsens the prognosis of patients. The traditional approach to the management of single lesions at accessible sites depends on neuro-surgical resection [1] but this line of attack is often contraindicated by such factors as the location of the lesion, the presence of multiple metastases, and difficulties in control of the original tumour or the existence of metastases outside the brain. If surgical excision is impossible, the median survival of untreated patients with cerebral metastases is less than three months [2] . In these circumstances, whole brain radiotherapy (WBRT) represents the standard treatment [3] but even so more than half of the patients die as a result of systemic tumour progression, and the median survival remains less than five months [4] . Alternative techniques of cerebral irradiation such as stereotactic radiotherapy or radiosurgery have been developed more recently but the precise indications for their optimal use remain to be defined by prospective randomised trials [5] [6] [7] Chemotherapy constitutes the principal approach to the treatment of disseminated NSCLC [8] [9] [10] and the combination of cisplatin and vinorelbine is one of the most active schedules [11, 12] . The difficulty experienced in penetrating the blood-brain barrier with cytotoxic drugs has meant that this approach has generally been viewed as ineffective for the treatment of brain metastases, however, several studies have demonstrated that chemotherapy can produce regression of intracranial secondaries [13] [14] [15] [16] and this has been repeatedly noted in patients with NSCLC [17] [18] [19] The explanation for this unexpected activity is thought to relate to physical disruption of the blood-brain barrier during growth of metastatic lesions on the surface of the brain. Additional evidence of efficacy and increase in the local response rate has been obtained from studies of concomitant radiotherapy and chemotherapy with positive results obtained using cisplatin-mitomycin-vindesine [20] , carboplatinteniposide [21] or carboplatin alone [22] . The increase in response rate has resulted in improved survival.
We wished to compare two treatment schedules both combining chemotherapy and radiotherapy for the management of NSCLC with cerebral metastases. The standard treatment in our study consisted of chemotherapy alone as initial treatment (given for a minimum of two cycles unless progression occurred) followed by cranial irradiation. The choice of radiotherapy schedule (30 gray (Gy) in 10 fractions over 12 days) was made on the basis of the results of randomised trials in particular that of RTOG [23, 24] which reported equivalent efficacy for 40 Gy in four weeks, 30 Gy in two weeks and 20 Gy in one week both in respect of relief of neurological symptoms and survival. The sequential approach in which chemotherapy was followed by cranial irradiation was designed to permit control of the systemic manifestations of the tumour while allowing use of cranial irradiation in case of failure to control cerebral lesions
The experimental arm of the study involved the use of identical chemotherapy with a combination of cisplatin and vinorelbine but with cranial irradiation starting as soon as the chemotherapy was initiated. This approach was justified by the hypothesis that cerebral metastases might progress swiftly and require the control provided by early use of radiotherapy.
We here report the results of this multicenter prospective randomised trial which sought to establish the optimal timing of cranial irradiation. The object of this trial was to compare early with late cranial irradiation in patients presenting with NSCLC with one or more inoperable brain metastases also treated with chemotherapy; the analysis was undertaken in the context of known prognostic factors [25, 26] .
Patients and methods

Eligibility
Patients were required to have histologically or cytologically documented NSCLC, at least one measurable (diameter > 10 mm) and inoperable brain metastasis documented by either computed tomography (CT) scan or magnetic resonance imaging (MRI), MRI scan was required in all cases to confirm that a brain metastasis was single in nature, no prior chemotherapy or brain radiotherapy, previous surgery and/or chest radiotherapy for the primary lung lesion was permitted prior to inclusion, although the status of the primary tumour had to be described (controlled or not) at the time of inclusion, no previous history of malignancy except nonmelanoma skin cancer, in situ carcinoma of the cervix, age > 18 and <75 years, ECOG performance status 2 or less, good renal (serum creatinine level < 1.5 ml/dl and/or creatimne clearance 60 ml/min), hepatic (serum bihrubin level I 5 mg/ dl), and haematological (absolute neutrophils count I 5 x IO 9 /I and platelet count 100 x 10 9 /l) functions, no recent (<3 months before the date of treatment) myocardial infarction and no active congestive heart failure or cardiac arrhythmia requiring medical treatment, no uncontrolled infectious disease Patients had to be accessible for follow-up and to have provided informed consent All patients underwent the following investigations before inclusion chest X-ray and fiberoptic bronchoscopy, CTscan or MRI of the brain, chest CTscan (including upper abdomen and adrenals), liver CT scan or ultrasonography, bone scan, and electrocardiogram, appropriate laboratory studies' complete blood cell count, serum chemistries (protein, calcium, glucose, blood urea nitrogen, creatinine, bihrubin, alkaline phosphatase, lactate dehydrogenase, and alanine aminotransferase), and electrolytes (Na+, K+, C1-, bicarbonate). Each patient who fulfilled the inclusion criteria was randomly allocated to one of two groups Initial neurological status of patients was recorded using Order's classification [28] Therapy Patients were randomly assigned to receive chemotherapy alone for at least the two first cycles or chemotherapy and early concurrent whole brain radiotherapy (WBRT) Chemotherapy consisted of cisplatin 100 mg/m 2 , diluted in 500 ml of 2% saline and administered intravenously (l v) over three hours after an infusion with 500 ml of 10% mannitol on day I of each cycle with adequate hydration Vinorelbine (Navelbine®) 30 mg/m 2 , diluted with 125 ml of normal saline, was administered I v, infused over 10 minutes, and followed for the next 10 minutes by another 125 ml of normal saline, on days 1, 8, 15, and 22 of each cycle Antiemetics were administered according to the standard practice in each institution at the time of the study. Courses were repeated every four weeks according to the tolerance and the tumour response The doses were modified on the basis of blood counts and tests of renal and hepatic function on the day of therapy Vinorelbine was given at half the initially planned dose if the patient had WHO grade 2 neutropenia and was withheld in the event of grade 3-4 neutropenia Cisplatin was administered at 50% of the initial dose if the serum creatinine level increased above 1 5 mg/dl It was discontinued if it increased beyond 3 mg/dl, even if it returned to normal values Treatment was discontinued if grade 3 or 4 neurotoxicity occurred, or clinically evident hearing loss WBRT was started on day 1 for the patients assigned to both chemotherapy and radiation (group B) Cranial irradiation was given by lateral opposed fields to the whole brain delivered by *°Co or high energy (4 megaelectron volts) Patients received a total dose of 30 gray (Gy) over two weeks in daily fractions of 3 Gy (10 fractions) Methylprednisolone (or equivalent) was systematically given during WBRT and tapered off in the following two weeks Patients in group A received the same WBRT but the timing was deferred until there was evidence of disease progression (see study design) In arm A, chemotherapy was administered alone for the two first cycles, and continued for patients with complete or partial extracranial response to a maximum of six cycles WBRT was performed 1) at any time in the case of proved clinical progression of brain lesions, 2) after two or four cycles of chemotherapy in the case of stable lntracranial disease (concurrently with the third or fifth cycle, if applicable), 3) after six cycles of chemotherapy for the other patients
In arm B, chemotherapy started on day 1 and continued after two cycles for patients with complete or partial extracranial response, to a maximum of six cycles. WBRT started on day 1 concurrently for all patients of arm B Therefore responses were evaluated after two cycles of chemotherapy and before WBRT in arm A, and after two cycles of chemotherapy with concurrent early WBRT in arm B
Treatment evaluation
The main end point of the study was survival and secondary criteria were response and tolerance Responses were evaluated according to WHO criteria, after completion of two courses of chemotherapy (alone in arm A, and with early WBRT in arm B) Responses were evaluated during regular meetings of the GFPC group by at least three independent observers Intracranial response, extracranial response and overall response were evaluated Complete response (CR) was defined as the disappearance for at least four weeks of all signs of disease, and the absence of new lesions Partial response (PR) in measurable disease was defined as a four-week reduction of more than 50% in the sum of the products of the cross-sectional diameters of all measurable lesions, and the absence of new lesions. For disease that could be evaluated, regression was defined as a decrease in tumour size for more than four weeks that was agreed on by two independent observers Stable disease was defined as a reduction of less than 50% or an increase of less than 25% in the sum of the products of the cross-sectional diameters of all measured lesions and no clear-cut regression or progression of disease for at least eight weeks Progressive disease or relapse was defined as an increase greater than 25% in the sum of products of the crosssectional diameters of measured lesions, an increase in disease that could be evaluated, or the appearance of new lesions
The duration of objective response was calculated from the start of treatment until documented disease progression Survival was defined as the interval from the date of randomisation until the date of death or last follow-up Toxicities were graded according to WHO criteria
Statistical methods
The trial was a prospective, multicenter, randomised, nonblinded study. Patients were randomly assigned by the central office of the GFPC to receive cisplatin, vinorelbine and delayed WBRTor cisplatin, vinorelbine and concurrent early WBRT Randomisation was stratified according to the status of primary tumour (controlled versus uncontrolled), extent of systemic disease (extracranial metastatic disease or not) and number of brain metastases (single versus multiple)
A sample size of 156 patients was planned to detect 25% improvement in 6 months survival rate using one-sided test with an alpha of 0 05 and 95% power Assuming that 10% of the enrolled are lost to follow up about 172 patients had to be enrolled in total Secondary objectives included assessment of intracranial and extracranial responses, and incidences of toxicities
The Pearson x 2 test and Fischer's exact test were used to compare treatment groups with respect to baseline demographic characteristics, estimates of response rates and toxicities Survival was calculated from the day of study entry until the date of death Kaplan-Meier's method was used to estimate the survival curves, and the log-rank test was used to compare treatment groups with respect to survival.
Results
Characteristics of the patients
Between July 1995 and October 1997, 176 patients from 25 centers were included in the study. On 176 patients randomised, 5 were found to be ineligible (2 in arm A and 3 in arm B) because of small-cell lung cancer (2 patients), prior chemotherapy (1 patient) and nonmeasurable brain lesion (2 patients). Demographic data and prognostic factors of the 171 eligible patients are listed on Table 1 Although there was prospective stratification for status of primary tumour, extent of systemic disease and number of brain metastases, the two treatments groups were very similar with respect to patient age, sex, performance status and neurologic symptoms at time of inclusion. The majority of patients had good performance status, adenocarcinoma, uncontrolled primary tumour and multiple brain metastasis. 53% (arm A) and 48% (arm B) of patients had significant neurologic symptoms before the start of the treatment.
Treatment
The median number of cycles administered in each arm is shown in Table 2 . The relative dose-intensity of vinorelbine was 69%, respectively, in arm A and B. Dose- reductions were principally made as a consequence of neutropenia, and these were most common during weeks 3 and 7 as predicted by previously reported experience. There was no significant difference between the two arms either in terms of the number of cycles or the dose intensity of vinorelbine and cisplatin. Cranial irradiation was administered according to the protocol to 57 patients in arm A; 29 patients did not receive radiotherapy and of these 19 died early (due to either disease progression or other causes). In arm B, two patients did not receive cranial irradiation because of early death.
Response
Twenty-two patients were inevaluable for response (ten in arm A, twelve in arm B); seventeen suffered early deaths (occurring before the first evaluation but without clinical or radiological evidence of disease progression) and these were related to neutropenic sepsis (nine patients), pulmonary embolus (two patients), pneumonia (two patients), unknown causes (two patients) and renal failure (one patient). Four patients gave written consent and were entered into the trial but then withdrew before completing two cycles of treatment, and one Abbreviation ORR -objective response rate patient was withdrawn as a result of major haematological toxicity. Table 3 lists the results of evaluation of response reported on the basis of 'intention to treat'. Most responses were partial responses, and in arm A there were 27% objective responses of intracerebral disease, 35% for extracerebral lesions and an overall rate of response of 21% while with arm B these figures were 33%, 25% and 20%, respectively; these levels of response are not significantly different (P -0.85).
Among the 57 patients in arm A who received radiotherapy after chemotherapy, 10 (17.5%) achieved an objective response of intracerebral disease.
Survival and progression-free survival
At the time of this analysis, 82 and 83 patients had died on arm A and B, respectively. The cause of death was tumour progression in 88% and 81% of patients on arm A and B, respectively. The overall median survival time was 23 weeks and was similar in the 2 arms (24 and 21 
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Figure 3 Overall time to progression-free survival using Kaplan-Meier weeks, respectively; P = 0.83). The six months survival rate was 46% and 40%, respectively, on arm A and B. The median progression-free survival time was similar in both arms (13 and 11 weeks, respectively; P = 0.92).
Figures 2 and 3 depict overall survival and progressionfree survival, respectively, in all randomised patients.
Toxicity
There were 13 toxic deaths: 6 on arm A (6 9%) and 7 on arm B (8.2%). Ten of these deaths were due to sepsis during severe neutropenia, four of which occurred on arm A (during the first cycle of treatment) and six on arm B (five during the first cycle and one after the fourth cycle). One patient on arm A and one patient on arm B died of pneumonia without neutropenia after the second cycle. One patient on arm A died of renal failure after the first cycle.
Haematologic toxicity, I e., leukopenia, neutropenia, thrombocytopenia and anaemia, were not significantly different between the two arms ( Table 4 ). The principal haematological toxicity was granulocytopenia: 55% of patients experienced either grade 3 or 4 neutropenia. Febrile neutropenia and infectious episodes were similar in the two arms. Table 5 lists the details of non-haematologic serious side effects. Neurotoxicity (grade > 2) was the major nonhaematologic toxicity (14 patients) and was not different between the two arms. More major neurotoxicity was observed in arm B (nine patients) than in arm A (five patients), but this difference was not statistically significant (P = 0.25). There were more neuro-cortical and neuro-hearing toxicities on arm B (seven patients) than in arm A (two patients) {P = 0.09). Neuro-cortical toxicity consisted of confusion (one patient), coma (two patients), seizures (one patient), worsening of Parkinson's disease 9 3) 15 (174) 30 (34 8) 6(6 9) 2(2 3) 3 (3 4) Arm B(n = 85)
17 (20 0) 0(0) 21 (24 7) 17 (20 0) 18 (21 1 (one patient) without evidence by clinical criteria or CT scan of intracranial tumour progression. The median time before neurocortical toxicity developed was 11 weeks and for ototoxicity 17 weeks. Renal toxicity (grade > 2) was observed only in arm A (three patients). Infection and vomiting were similar in the two arms. These side effects required treatment discontinuation Apart from alopecia, which was present in all patients who received the WBRT, the other non-haematologic side effects were unfrequent.
Symptom control
Formal quality-of-life assessment was not performed in this study.
Discussion
We report here the first large randomised trial to examine the contribution of chemotherapy to the management of brain metastases from NSCLC. The timing (early or delayed) of brain radiotherapy does not produce any significant differences in survival when these patients are treated with chemotherapy. There was no significant difference in our study between the objective cerebral or global response rates Despite the classical concept of the blood-brain barrier, chemotherapy alone (arm A) appears to produce a 27% objective response rate in the brain, while this was not statistically significant from the 33% rate obtained by early administration of WBRT associated with the chemotherapy. This lack of difference is also apparent in terms of the global objective response rates (20 vs. 21%) and median survival time (24 vs. 20 weeks). Administration of early WBRT (arm B), however, produces a considerably greater proportion of complete responders within the brain (7 vs. 1), which would appear to indicate that the association of chemotherapy with early radiotherapy provides better cerebral control of the disease. The standard treatment in our trial (arm A) involved chemotherapy alone (over a minimum of two cycles in the absence of progression) and delayed brain irradiation, administered depending on the cerebral response. This choice was based on the fact that chemotherapy is the major treatment for metastatic NSCLC [8] [9] [10] . Chemotherapy is also recognised to be effective on brain metastases of NSCLC from several phase II trials [13] [14] [15] [16] [17] [18] [19] . The sequential regimen of chemotherapy followed by WBRT enables treatment of the systemic disease and, if local failure of treatment occurs in the brain, the use of brain radiation. The trial arm (arm B) involved the same chemotherapy, although WBRT was administered immediately, from the first day of chemotherapy. This concomitant regimen is based on the phase U trials which have reported significant benefit [20] [21] [22] and was justified by the assumption that brain metastases progress rapidly, requiring early, immediate WBRT. We did not wish to add a third arm involving radiotherapy alone, whether or not followed by chemotherapy. Although whole brain radiotherapy alone is considered to be standard treatment, it does not provide control for the systemic disease. We had considered that chemotherapy administered after radiotherapy could be less effective, because of vascularization problems and delayed start of the systemic treatment. This assumption is questionable and the behaviour consisting in administering first brain radiotherapy, and then chemotherapy, is also a widespread habit for the treatment of brain metastases. But our study design took into account the therapeutic habits of our group, the GFPC, which integrates early chemotherapy for the treatment of brain metastases The activity of combination chemotherapy with cisplatin-vinorelbine against brain metastases of NSCLC is demonstrated by the results obtained in arm A, and this study is the first randomised trial to confirm the activity of chemotherapy in the treatment of intracranial disease. Although the response rate of 27% in cerebral metastases is lower than that reported in phase II trials of other agents [16] [17] [18] , this is a frequent feature of results obtained in larger randomised trials and may reflect the reduction of selection bias. It is also worth noting that the objective response rate for brain metastases is not different from that achieved for extracranial lesions (35% in arm A or 25% for arm B) and the level of activity of the chemotherapy in this trial justifies the use of systemic chemotherapy in this clinical setting.
The objective overall response rates achieved with combination cisplatin-vinorelbine were 21% in arm A and 20% for arm B (P = 0.85) and these results are consistent with response rates reported for stage IV NSCLC by GFPC using cisplatin-mitomycin C-vinorelbine [29] (overall response rate 20%) or the study reported by Wozniak [30] in which 91% of patients had stage IV disease and the overall response rate was 26%, despite the fact that the presence of brain metastases was a cause of exclusions from these trials. It seems reasonable to conclude that it is possible to include these patients in trials of systemic chemotherapy and anticipate that they will obtain comparable levels of benefit to that achieved by other patients with advanced NSCLC. Despite the evidence of activity of the cisplatin-vinorelbine combination administered either alone or in combination with cranial irradiation, the median survival in this group of 21-24 weeks is shorter than that achieved in other trials of the same chemotherapy from which patients with brain metastases were excluded for which median survivals of 31-40 weeks are reported [11, 12] . The poor results relate in part to high rates of toxic deaths during the initial eight weeks of treatment which are probably a consequence of a combination of the dose schedule of vinorelbine and the advanced stage of the underlying disease. Nonetheless, despite the toxicity of the treatment, the median survivals achieved in this trial are an improvement compared to those reported for cranial irradiation alone which he in the range of 2.3-3.3 months [31, 32] .
Early addition of WBRT (arm B) may allow us to improve the control of brain metastases compared to chemotherapy alone followed by brain radiation. This had been suggested by the only published randomised trial involving chemotherapy for brain metastases of lung cancer [33] . This trial appeared to indicate that WBRT provided an additive effect together with chemotherapy using the association of chloroethylnitrosourea and Tegafur. This was, however, in a small number of patients, some of whom were suffering from small cell cancer and no significant differences were produced Our study also does not detect any significant difference between the cerebral response rates in the two arms. The higher proportion of complete cerebral responders in the arm involving early WBRT suggests that the association of chemo-and radiotherapy provides better cerebral control than chemotherapy alone. We would have had to measure the time taken for progression in our trial, differentiating between cerebral and extracerebral sites Similarly, we would have had to differentiate deaths due to cerebral progression from other causes amongst the causes of death due to progression. Lastly, we should have measured the progression of neurological symptoms which could have also been an indicator for the progression of brain metastases. These are very difficult measurements to perform, but would perhaps have enabled us to evaluate and compare the control of cerebral disease in greater detail.
Early cranial irradiation would not appear to improve survival either, but this lack of effect may simply reflect the similarities in the two schedules subjected to comparison; the majority of patients in arm A (57 out of 86) received cranial irradiation even though this was administered later than the patients in arm B. The study design was constructed to detect a difference of 25% in the survival rates at six months, and it is possible that a smaller difference would not have been detected by the statistical analysis.
The major toxicity associated with treatment in this trial was neutropenia (grade 3-4) which was experienced by 55% of patients and contributed to an increased rate of death from infection (5.8% of patients). There was no significant difference between the two arms of the trial, but previous published experience would attribute this effect to the administration of vinorelbine. The schedule for administration of vinorelbine and the rules for dosemodification in relation to haematological monitoring were derived from those used in the trial published by Le Chevalier [12] , but were combined with a reduced dose of cisplatin at 100 mg/m 2 instead of 120 mg/m 2 The use of growth factors such as G-CSF was not permitted within the protocol, and this may account both for the lower dose-intensity of vinorelbine (65% against 71%) and the greater haematological toxicity. It might also be relevant that inclusion in the trial was only open to patients with cerebral metastatic lesions large enough to measure, and although their Performance Status lay between 0 and 2 (ECOG) many were symptomatic from their metastases; by contrast, studies of other patients with brain metastases (especially small-cell lung cancer) often require patients to be a-symptomatic. This group of patients with significant neurologic symptoms are frequently more frail, so it might have been preferable to use a lower dose of vinorelbine; a schedule of 25 mg/m 2 /week (together with cisplatin 100 mg/m 2 /cycle) has been reported to give a similar rate of granulocytopenia at 59% but a reduced number of toxic deaths (1%) in patients with extracranial metastatic disease [30] .
The development of neuro-cortical toxicity has not been previously reported to be produced by cisplatinvinorelbine in combination, and the median time (11 weeks) is too short to suggest the possibility that it was induced by the cranial irradiation; neither can in that proportion of patients who showed evidence of response, the changes be reasonably attributed to progression of the underlying disease. It is possible that synergistic toxicity to the neuro-cortex may result from concomitant chemotherapy and cranial irradiation but we definitively cannot exclude the aetiology of a tumour progression in the central nervous system, not visible by standard CTscan. Similarly, the incidence of late ototoxicity produced by this schedule is significant (median presentation 17 weeks) and while it may relate simply to the cumulative dose of cisplatin, a contribution from the cranial irradiation might result in the final incidence of 2.3%, and more particularly with the concomitant use of brain radiotherapy and an association of chemotherapy including cisplatinum, as it sometimes occurs in patients treated for medulloblastoma [34] . Because the overall survival in this trial is relatively short (20-24 weeks) other late effects of cranial irradiation such as dementia or ataxia may be underestimated because they do not usually present until months or years after the end of treatment Our trial has not made it possible to establish the optimal timing for radiotherapy when given in association with chemotherapy for patients with inoperable brain metastases from NSCLC. We have, however, confirmed that chemotherapy has a level of activity against mtracranial disease which is not different from that achieved in other sites The presence of inoperable brain metastases should not therefore alter the treatment approach to patients with metastatic NSCLC; disseminated disease requires systemic treatment and this is provided by the use of chemotherapy.
Nevertheless, the short survival of these patients justifies a continued search for treatment which is both better tolerated and more effective. 
